COAPT试验:心衰合并二尖瓣反流患者健康状况变化与结局
COAPT试验纳入551例心衰合并重度继发性二尖瓣反流且经最大耐受GDMT仍症状的患者,评估1个月内KCCQ-OS变化与1个月至2年死亡或心衰住院复合终点的关联。TMVr组58% vs GDMT组26%实现KCCQ-OS≥10分改善;KCCQ-OS每增加10分,复合终点风险降低14%(HR 0.86,95%CI 0.81-0.92,P<0.001),校正后HR 0.79(95%CI 0.73-0.86,P<0.001)。
要点
- TMVr较单纯GDMT更易实现1个月内KCCQ-OS≥10分改善(58% vs 26%)。
- KCCQ-OS早期改善与1个月至2年死亡或心衰住院风险降低独立相关。
- 连续KCCQ-OS评估有助于识别长期预后不良的高危患者。
核心结论
- 在心衰合并重度继发性二尖瓣反流患者中,短期疾病特异性健康状况变化与后续长期死亡或心衰住院风险强烈相关。
- 系列KCCQ-OS评估具有预后价值,可识别长期临床结局不良风险患者。
研究设计与样本
- COAPT试验的事后分析,评估基线至1个月KCCQ-OS变化与1个月至2年死亡或心衰住院复合终点的关联。
- 分析人群为551例心衰合并重度继发性二尖瓣反流且1个月时存活的患者。
- 检验TMVr或单纯GDMT是否修饰该关联。
主要发现
- TMVr组58%、GDMT组26%实现基线至1个月KCCQ-OS≥10分改善。
- KCCQ-OS早期改善与1个月至2年死亡或心衰住院风险呈负相关(p<0.001)。
- KCCQ-OS每增加10分,死亡或心衰住院风险降低14%(HR 0.86;95%CI 0.81-0.92;p<0.001),与治疗组无显著交互(pinteraction=0.17)。
- 校正人口学和临床因素后,KCCQ-OS变化与结局的关联增强(HR 0.79;95%CI 0.73-0.86;p<0.001)。
临床怎么用
- 对心衰合并重度继发性二尖瓣反流患者,可系列评估KCCQ-OS以识别长期预后不良高危者。
- 短期KCCQ-OS改善可作为TMVr或GDMT治疗后长期结局的早期预后指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation) trial, transcatheter mitral valve repair (TMVr) with the MitraClip rapidly improved health status and reduced the long-term risks for death and heart failure (HF) hospitalization in patients with HF and severe secondary mitral regurgitation who remained symptomatic despite maximally tolerated guideline-directed medical therapy (GDMT). OBJECTIVES: The aim of this study was to examine if early health status changes were associated with long-term clinical outcomes in the COAPT population. METHODS: The association between change in health status (Kansas City Cardiomyopathy Questionnaire overall summary score [KCCQ-OS]) from baseline to 1 month and the composite rate of death or HF hospitalization between 1 month and 2 years in the COAPT trial were evaluated, and whether treatment (TMVr or GDMT alone) modified this association was tested. RESULTS: Among 551 patients with HF and severe secondary mitral regurgitation who were alive at 1 month, those randomized to TMVr were more likely than those randomized to GDMT alone to achieve a ≥10-point improvement in KCCQ-OS from baseline to 1 month (TMVr, 58%; GDMT alone, 26%). Early improvement in KCCQ-OS was inversely associated with the risk for death or HF hospitalization between 1 month and 2 years (p < 0.001). When analyzed as a continuous variable, a 10-point increase in KCCQ-OS was associated with a 14% lower risk for death or HF hospitalization (hazard ratio: 0.86; 95% confidence interval: 0.81 to 0.92; p < 0.001), with no significant interaction with treatment group (pinteraction = 0.17). After adjusting for demographic and clinical factors, the association between change in KCCQ-OS and outcomes was strengthened (hazard ratio: 0.79; 95% confidence interval: 0.73 to 0.86; p < 0.001). CONCLUSIONS: In patients with HF and severe secondary mitral regurgitation, a short-term change in disease-specific health status was strongly associated with the subsequent long-term risk for death or HF hospitalization. These findings reinforce the prognostic utility of serial KCCQ-OS assessments to identify patients at risk for poor long-term clinical outcomes in this population. (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation [The COAPT Trial]; NCT01626079).
引用
- Arnold SV, Stone GW, Mack MJ, et al. Health Status Changes and Outcomes in Patients With Heart Failure and Mitral Regurgitation: COAPT Trial. J Am Coll Cardiol. 2020. PMID: 32194195. doi:10.1016/j.jacc.2020.03.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。